2.1. Study Design
Atherosclerosis
ATHEROSCLEROSIS, DYSLIPIDEMIA
This open-label randomized pilot study enrolled eligible hemodialysis patients with dyslipidemia, who were randomized using a stratified block randomization method to receive either conventional therapy alone (control group) or conventional therapy with add-on high-dose EPA/DHA treatment (1860 mg of EPA and 1500 mg of DHA; high-dose EPA/DHA group) for 3 months. The conventional therapy used in the present study included administering antiplatelet agents (if necessary), lipid-lowering drugs (mainly statins at appropriate doses), and antihypertensive drugs, as recommended by the Japan Atherosclerosis Society guidelines [